NICOX SA EUR1 (NASDAQ:NICXF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Friday.

According to Zacks, “Nicox is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, they are building a diversified portfolio of ophthalmic products that can help people to enhance their sight. Nicox’s advanced pipeline features two pre-NDA candidates (Vesneo for glaucoma, partnered with Bausch + Lomb / Valeant and AC-170 for allergic conjunctivitis) as well as two pre-MAA candidates (AzaSite for bacterial conjunctivitis and BromSite for pain and inflammation after cataract surgery). The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe’s five largest markets complemented by an expanding international network of distributors. Nicox is headquartered in France and has more than 120 staff worldwide. It is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. “

Shares of NICOX SA EUR1 (NASDAQ:NICXF) opened at 8.086 on Friday. The firm has a 50 day moving average price of $8.72 and a 200-day moving average price of $11.11. The company’s market cap is $184.75 million. NICOX SA EUR1 has a 12 month low of $1.69 and a 12 month high of $14.75.

5 Day Chart for NASDAQ:NICXF

Receive News & Stock Ratings for NICOX SA EUR1 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NICOX SA EUR1 and related stocks with our FREE daily email newsletter.